CSIMarket
 


Cyclacel Pharmaceuticals Inc   (CYCC)
Other Ticker:  
 
 

CYCC's Revenue Growth by Quarter and Year

Cyclacel Pharmaceuticals Inc 's Revenue results by quarter and year




CYCC Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 0.00 0.00 0.00
III Quarter September 0.02 0.00 0.00 0.00
II Quarter June 0.37 0.00 0.00 0.00
I Quarter March 0.00 0.00 0.00 0.00
FY   0.39 0.00 0.00 0.00



CYCC Revenue third quarter 2023 Y/Y Growth Comment
Cyclacel Pharmaceuticals Inc in the third quarter 2023 achieved Revenue of $ 0.02 millions compare to recorded in same quarter a year ago.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 234 other companies have achieved higher Revenue growth. While Cyclacel Pharmaceuticals Inc ' s Revenue no change of % ranks overall at the positon no. 3598 in the third quarter 2023.




CYCC Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Cyclacel Pharmaceuticals Inc 's third quarter 2023 Revenue $ 0.02 millions CYCC's Income Statement
Cyclacel Pharmaceuticals Inc 's third quarter 2022 Revenue $ 0.00 millions Quarterly CYCC's Income Statement
New: More CYCC's historic Revenue Growth >>


CYCC Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September -95.68 % - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #235
Healthcare Sector #606
Overall #3598

Revenue Y/Y Growth Statistics
High Average Low
141.55 % 4.26 % -95.71 %
(Sep 30 2015)   (Sep 30 2023)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #235
Healthcare Sector #606
Overall #3598
Revenue Y/Y Growth Statistics
High Average Low
141.55 % 4.26 % -95.71 %
(Sep 30 2015)   (Sep 30 2023)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Cyclacel Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
141.55 % 4.26 % -95.71 %
(Sep 30 2015)  


CYCC's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Cyclacel Pharmaceuticals Inc realized fall in Revenue sequentially by -95.68% to $ 0.02 millions, from $ 0.37 millions released a quarter before.

Within Major Pharmaceutical Preparations industry 234 other companies have achieved higher Revenue quarter on quarter growth. While Cyclacel Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 3598.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #235
Healthcare Sector #606
Overall #3598
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #235
Healthcare Sector #606
Overall #3598
Revenue Q/Q Growth Statistics
High Average Low
141.55 % 4.26 % -95.71 %
(Sep 30 2015)  


CYCC's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Cyclacel Pharmaceuticals Inc disclosed fall in Revenue sequentially by -95.68% to $ 0.02 millions, from $ 0.37 millions declared a quarter before.

Within Major Pharmaceutical Preparations industry 234 other companies have achieved higher Revenue quarter on quarter growth. While Cyclacel Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 3598.


Cyclacel Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #




Cumulative Revenue growth Comment
In the Sep 30 2023 period, Cyclacel Pharmaceuticals Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Cyclacel Pharmaceuticals Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Sep 30 2023 period, Cyclacel Pharmaceuticals Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Cyclacel Pharmaceuticals Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CYCC's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for CYCC's Competitors
Revenue Growth for Cyclacel Pharmaceuticals Inc 's Suppliers
Revenue Growth for CYCC's Customers

You may also want to know
CYCC's Annual Growth Rates CYCC's Profitability Ratios CYCC's Asset Turnover Ratio CYCC's Dividend Growth
CYCC's Roe CYCC's Valuation Ratios CYCC's Financial Strength Ratios CYCC's Dividend Payout Ratio
CYCC's Roa CYCC's Inventory Turnover Ratio CYCC's Growth Rates CYCC's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2023
Procyon Corporation-0.22%$ -0.221 millions
Amedisys Inc -0.31%$ -0.314 millions
Karyopharm Therapeutics Inc -0.38%$ -0.376 millions
Establishment Labs Holdings Inc -0.50%$ -0.505 millions
Opko Health Inc -0.64%$ -0.639 millions
Integra Lifesciences Holdings Corp-0.72%$ -0.719 millions
Healthcare Services Group Inc -0.75%$ -0.748 millions
Phibro Animal Health Corporation-0.77%$ -0.772 millions
Bellicum Pharmaceuticals Inc -0.89%$ -0.890 millions
Prestige Consumer Healthcare Inc -1.12%$ -1.125 millions
Sharecare Inc -1.13%$ -1.127 millions
Lifevantage Corp-1.14%$ -1.140 millions
Organon and Co -1.17%$ -1.171 millions
Optinose Inc -1.27%$ -1.270 millions
Baxter International Inc -1.72%$ -1.723 millions
Puma Biotechnology Inc -1.73%$ -1.727 millions
Blueprint Medicines Corporation-1.76%$ -1.763 millions
Standard Biotools Inc -1.92%$ -1.918 millions
Pacira Biosciences inc -2.11%$ -2.114 millions
Bristol myers Squibb Company-2.25%$ -2.246 millions
Aurinia Pharmaceuticals Inc -2.27%$ -2.266 millions
Abbott Laboratories-2.56%$ -2.565 millions
Enhabit Inc -2.79%$ -2.785 millions
Novocure Limited-2.81%$ -2.807 millions
Uniqure N v -2.90%$ -2.899 millions
Vaso Corporation-2.92%$ -2.925 millions
Scientific Industries Inc -3.16%$ -3.165 millions
Akumin Inc -3.21%$ -3.205 millions
Syros Pharmaceuticals Inc -3.32%$ -3.315 millions
Viatris Inc -3.34%$ -3.342 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com